NEI Research News

Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood.

In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged by blinding diseases.

A team of scientists have created a molecular catalog that describes the different types of retinal ganglion cells in zebrafish, linking them to specific connections, functions, and behaviors.

Surgical and injectable drug approaches are equally effective for treatment of bleeding inside the eye from proliferative diabetic retinopathy (PDR), according to a National Eye Institute (NEI)-supported clinical study from the DRCR Retina Network .

A new study shows that deleting one of the inhibitors of the RPE65 gene in a mouse model that carries a human disease mutation prevents degeneration of cone photoreceptors that are used for daytime high-resolution color vision.

Scientists at Scripps Research have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy.

The National Eye Institute (NEI) Audacious Goals Initiative (AGI) is exploring the possibility that the natural world holds the keys to restorative therapies that might unlock regenerative powers in humans.

Oklahoma Medical Research Foundation scientists have identified a compound that could give birth to therapies for a host of eye diseases that include retinopathy of prematurity and diabetic retinopathy.

NEI-funded scientists are hacking the zebrafish’s innate regenerative capacity to learn how to treat human disease.